Corporate Banner
Satellite Banner
Biologics & Bioprocessing
Scientific Community
Become a Member | Sign in
Home>News>This Article

13th DCVMN Conference: DCVMN Must Become Stronger

Published: Monday, November 05, 2012
Last Updated: Monday, November 05, 2012
Bookmark and Share
Through establishing greater cooperation throughout the developing world on vaccine research and development.

The Developing Countries Vaccine Manufacturers Network (DCVMN) can become stronger, especially in establishing cooperation on vaccine research and development.

"DCVMN can be stronger. We have to increase vaccine availability and to improve the quality of vaccine production in developing countries," said out-going DCVMN President Akira Homma at the closing ceremony of 13th DCVMN Annual General Meeting in Kuta Bali.

Homma said DCVMN countries have committed to increasing their efforts to develop vaccines to prevent millions of deaths caused by infectious disease.

Therefore the network members must share the technology and know-how to develop the capacity to produce over 40 vaccine types that would contribute to preventing 2,5 million deaths each year, as estimated by WHO.

Homma also said that Bio Farma is an example of a successful vaccine maker in the developing world not only for being able to produce various types vaccines prequalified by the WHO, but for its initiatives and cooperation on vaccine research with many developing countries as well.

Homma, of Brazil's Bio-Manguinhos-Fiocruz vaccine manufacturer, pointed out the leading role Bio Farma had taken up in 1999 when WHO sponsored steps for the developing countries to jointly develop their capabilities in vaccine research and making.

Homma added that the largest amount of vaccines bought by WHO are produced in the developing countries as they are of the same high quality as those produced in the industrialized world, with lower prices.

The newly-elected president of the DCVMN, Mahendra Suhardono of Bio Farma, expressed his optimism that the organization could be better and become stronger, especially under his leadership for the next two years.

"We commit to increasing cooperation and technology transfer in order to increase vaccine production among developing countries in large quantities and at affordable prices. We don't only want to be sustainable, but we commit to delivering vaccines to more people as well," said Mahendra Suhardono.

Mahendra also stated that Bio Farma has offered cooperation to other developing countries. Two countries which have developed cooperation with Bio Farma are India and South Africa. So far Bio Farma has produced eleven types of vaccine, all WHO pre-qualified.

According to Mahendra, Indonesia has already achieved a "sound, technological platform" in vaccine production and therefore looks forward to establishing cooperation in vaccine research and developments with other DCVMN member countries.

The 13th DCVMN Annual General Meeting in Kuta Bali was attended by more than 100 vaccine experts and high ranking health officials from DCVMN member states and other countries as well as UN bodies.

The meeting also feature presentations and discussions from vaccine experts and government officials from the United States, Europe, Latin America and U.N. bodies.

The 14th DCVMN Annual General Meeting will be held next year in Vietnam.

Further Information
Access to this exclusive content is for Technology Networks Premium members only.

Join Technology Networks Premium for free access to:

  • Exclusive articles
  • Presentations from international conferences
  • Over 2,800+ scientific posters on ePosters
  • More than 4,000+ scientific videos on LabTube
  • 35 community eNewsletters

Sign In

Forgotten your details? Click Here
If you are not a member you can join here

*Please note: By logging into you agree to accept the use of cookies. To find out more about the cookies we use and how to delete them, see our privacy policy.

Scientific News
"Good" Mozzie Virus Might Hold Key to Fighting Human Disease
Australian scientists have discovered a new virus carried by one of the country’s most common pest mosquitoes.
World’s First Therapeutic Venom Database
Open-source library describes nearly 43,000 effects on the human body.
Speeding Up the Process of Making Vaccines
System uses a freeze-dry concept to develop "just-add-water" solution.
Surprising Trait Found in Anti-HIV Antibodies
Scientists at The Scripps Research Institute (TSRI) have new weapons in the fight against HIV.
New Method Identifies Up to Twice as Many Proteins and Peptides
An international team of researchers developed a method that identifies up to twice as many proteins and peptides in mass spectrometry data than conventional approaches.
The Do’s and Don’ts of SPR Experiments
Surface Plasmon Resonance (SPR) is a technique that is becoming more widely used, particularly by anyone who wants to obtain accurate on (association) and off (dissociation) rates for biomolecular binding.
Genetically Engineering Algae to Kill Cancer Cells
New interdisciplinary research has revealed the frontline role tiny algae could play in the battle against cancer, through the innovative use of nanotechnology.
Novel Stem Cell Line Avoids Risk of Introducing Transplanted Tumors
Progenitor cells might eventually be used to repair or rebuild damaged or destroyed organs.
Single Vaccine for Chikungunya, Related Viruses May be Possible
What if a single vaccine could protect people from infection by many different viruses? That concept is a step closer to reality.
Blocking the Transmission Of Malaria Parasites
Vaccine candidate administered for the first time in humans in a phase I clinical trial led by Oxford University’s Jenner Institute, with partners Imaxio and GSK.

Skyscraper Banner
Go to LabTube
Go to eposters
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
2,800+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
4,000+ scientific videos